Carolina Acute Care & Wellness Center, P.A.

12/09/2025

12/08/2025

Now in Phase 3 Trials. Like an oral Repatha as an alternative to statins with 58% lowering of cholesterol in early trials.

The drug enlicitide reduced cholesterol for adults with high levels due to an inherited disorder and may also work for a broader population.

12/07/2025

Moderation is key: Patients should feel free to enjoy the holidays while trying to maintain basic dietary guidelines.

12/07/2025

New Mechanisms Offer Alternatives as other Drugs are in development that will allow clinicians & patients more options if GLPs are no longer working effectively. We are watching these Research Trials closely.

Maridebart cafraglutide (MariTide) is a drug in development that blocks GIP while activating GLP-1. It may only require a monthly or bimonthly dose. Such alternatives could help patients who don’t respond to current therapies and increase their adherence to treatment.

Although GLP-1s have proven successful for many, they are not “one size fits all” medications. With the continued advancement of these drugs, clinicians will have appealing alternatives to offer patients who have not had success with or have not tolerated GLP-1s.

Bottom line: The next generation of obesity drugs is more diverse and potentially more effective. New mechanisms, oral options, and multitargeted therapies will allow more personalized treatment for patients.

Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide recep...

12/07/2025

Phase 2 Drug Trials we're monitoring that are entering the next phase of Research.

Retatrutide targets three different receptors: GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon, aiming to reduce appetite and increase fat burning.

In a phase 2 trial, it led to up to 24.2% weight loss in just less than a year. Researchers note that the effectiveness of retatrutide can be compared to that of bariatric surgery.

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effe...

12/07/2025

Some patients who avoid injections will soon have oral versions of GLP-1s as a delivery option. A phase 3 clinical trial of people taking oral semaglutide at 50 mg a day showed up to 15.1% weight loss compared to those who took a placebo. The oral, small-molecule, nonpeptide GLP-1 receptor agonist orforglipron has displayed promising results for weight loss and is currently in late-stage trials.

People who received a daily 50-mg dose of oral semaglutide, a glucagon-like peptide-1 receptor agonist, experienced greater weight loss than those who received a placebo pill, according to results from a 68-week phase 3 clinical trial that included 667 adults with obesity or overweight and 1 or more...

12/07/2025

This is about the Surmount-4 Trial.
The study found that though GLP have become Miracle Drugs, their effects obviously end when patients stop taking them.

Microdosing to maintain weight is one strategy for long-term benefit, but has not been fully studied yet, and holds promise.

We knew the weight would return, but what happens to the other benefits when patients are no longer taking GLP-1 drugs?

12/06/2025

Christmas at Carolina Acute Care & Wellness Center

This season, we are reminded just how blessed we are.
Today we celebrated more than a Christmas party—we celebrated being with coworkers that we love.

Our team isn’t just the best medical staff anywhere… they are friends who truly care, who show up every day with compassion, dedication, and a heart for serving our community.

In a year full of challenges and victories, we’re grateful for the people who make our mission of Scholarship • Service • Stewardship come alive.

From all of us at Carolina Acute Care & Wellness Center,
Merry Christmas—and thank you for trusting us with your care.

11/27/2025

Medical Strategies for staying healthy & on goal this Holiday Season. Enjoy Everything in small, balanced portions.
Happy Thanksgiving...

11/27/2025

Thankful for our community - Humbly serving up a small portion of its Healthcare.

From the staff at Carolina Acute Care & Wellness Center, P.A. & our growing Carolina Executive Park, soon to house even more medical & community services -
Have a Happy & Safe Thanksgiving!

If you haven't already: Consider following Carolina Executive Park for updates of the parent facility - https://www.facebook.com/profile.php?id=100094182901552

11/25/2025

Happy Thanksgiving with a bit of Medical Humor.

We're closed Wednesday & Thursday of this week for the Holiday. OPEN Monday, December 1st.